MedTrace Logo

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

NCT04985812 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-05-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and tolerability of JNJ-67484703 administrations in participants with active rheumatoid arthritis (RA).

Conditions

Interventions

DRUG

JNJ-67484703

Participants will receive JNJ-67484703.

DRUG

Placebo

Participants will receive placebo to JNJ-67484703.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-18
Primary Completion
2023-05-18
Completion
2023-05-18
FDA Drug
Yes

Countries

  • United States
  • Georgia
  • Hungary
  • Moldova
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04985812 on ClinicalTrials.gov